Depression caused by common treatment for hepatitis C may affect outcome

ATLANTAAn article appearing in the January 2005 issue of Brain, Behavior and Immunity suggests that developing depression while on interferon-alpha plus ribavirin may impact how well the medications work.

In a study conducted in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine, Charles L. Raison, MD, Andrew Miller, MD, and colleagues, observed that patients who develop depressive symptoms during interferon-alpha plus ribavirin therapy were significantly less likely to have cleared the hepatitis C virus from their blood following six months of treatment.

"Hepatitis C infection affects three to five million Americans, and is the leading cause of liver transplantation," said Dr. Raison. "With advances in treatment, 40-50 percent of patients can be cleared of the virus. Unfortunately, however, the current treatment for hepatitis C interferon-alpha plus ribavirin produces a high rate of psychiatric side effects that have long been recognized as impediments to successful antiviral therapy. In the past we primarily worried that depression interfered with quality of life, or would cause patients to stop taking the medicine. These new data suggest that even if patients stay on treatment, they are less likely to have a good outcome if they develop depression."

The study examined 103 participants who received pegylated interferon-alpha-2b plus ribavirin (PEG IFN/ribavirin). All participants were psychiatrically evaluated prior to initiation of the medication and at 4, 8, 12 and 24 weeks of PEG IFN/ribavirin treatment.

Only 34% of the patients who had a significant increase in depression cleared the hepatitis C virus from their blood at 24 weeks, as compared to 59%-69% of patients with milder increases in depression. The effect of depression on viral clearance persisted even after adjusting for factors known to affect treatment outcome, such as viral genotype, or whether medications had to

Contact: Kathi Baker
Emory University Health Sciences Center

Page: 1 2

Related medicine news :

1. Depression linked to insomnia in HIV patients
2. Depression may explain higher risk of heart attack associated with antidepressants
3. Depression predicts heart rhythm abnormalities in heart attack patients
4. Depression tied to higher risk of heart disease death
5. Depression predicts mortality in women with heart disease
6. Depression can lead to back pain
7. Depression on College Campuses conference
8. Depression may be a risk factor for heart disease, death in older women
9. Depression, other psychiatric illnesses common following traumatic brain injury
10. Depression, trauma stress linked to physical complaints
11. Depression doubles risk of death after bypass surgery

Post Your Comments:

(Date:11/25/2015)... Robles, CA (PRWEB) , ... November 25, 2015 ... ... non-surgical bunion treatment, is offering lower prices in an early celebration of the ... at the promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Todd S. ... offer laser services to many of his patients. Dr. Afferica now uses the BIOLASE ... reduce the amount of time the doctor uses other traditional cutting tools, such as ...
(Date:11/24/2015)... ... ... Charitable giving is at its peak during the holidays. In fact, nearly ... year totalling over $358 billion in 2014. With more than 1.5 million U.S. ... who want to “give back” during the holidays. , “With so many charities to ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced that ... Clinical Trial Supply East Asia Conference, to be held at the InterContinental Seoul ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Preparing for ... p.m. – 3:00 p.m. EST, http://www.fdanews.com/preparingldtreg , FDA has long asserted that ... regulations apply to performing the tests and do not meet the device regulations. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... -- st  Scientific Assembly and Annual Meeting of the ... place in Chicago on Nov-29 th ... st  Scientific Assembly and Annual Meeting of the Radiological Society ... Chicago on Nov-29 th through Dec-4 ... Dynamics will present its revolutionary whole body CZT digital SPECT/CT solution ...
(Date:11/24/2015)... LONDON , November 24, 2015 The uptake ... (T1DM), will be a key driver of market growth to 2021, ... of recently approved and pipeline premium products for Type 1 Diabetes Mellitus ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ...
(Date:11/24/2015)... San Diego -based Imprimis Pharmaceuticals, Inc. (NASDAQ: ... the development, production and dispensing of novel compounded ... therapeutic segments including ophthalmology, urology, sinus and integrative ... states from four facilities located in ... New Jersey and Pennsylvania.  ...
Breaking Medicine Technology:
Cached News: